Concepedia

Author

Bo Huang

Pfizer (United States)ORCID

Also Known As

B Huang, B. Huang, Bo HUANG, Bo Huang, Bo Huang (30906), Boda Huang, De-Jun Cui, Huang Bo, Huang, Bo

189

Publications

10.3K

Citations

36

H-Index

149

Concepts

All Affiliations

Pfizer (United States)Pfizer (Italy)Dana-Farber Cancer InstituteMemorial Sloan Kettering Cancer CenterInstitut Gustave Roussy
BH

About

Bo Huang is an author at Pfizer (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

28

1.4K

2

Health Sciences

8

8

146

3

Business

3

3

102

4

Engineering

2

2

83

5

Natural Sciences

2

2

94

Bo Huang

×

80

Publications

9.7K

Citations

34

H-Index

YearCitations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen,

New England Journal of Medicine

2019

2.5K

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Se Hoon Park, Éric Voog,

New England Journal of Medicine

2020

1.4K

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Antoni Ribas, Richard Kefford, Margaret Marshall,

Journal of Clinical Oncology

2013

811

Improving power and accuracy of genome-wide association studies via a multi-locus mixed linear model methodology

Shibo Wang, Jianying Feng, Wenlong Ren,

Scientific Reports

2016

520

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Toni K. Choueiri, Robert J. Motzer, Brian I. Rini,

Annals of Oncology

2020

453

Methodological implementation of mixed linear models in multi-locus genome-wide association studies

Yang-Jun Wen, Hanwen Zhang, Yuan-Li Ni,

Briefings in Bioinformatics

2016

381

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

Ki Y. Chung, Ira Gore, Lawrence Fong,

Journal of Clinical Oncology

2010

303

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Neil H. Segal, Aiwu Ruth He, Toshihiko Doi,

Clinical Cancer Research

2018

274

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Mario Sznol, Siwen Hu‐Lieskovan,

Clinical Cancer Research

2017

229

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Massimo Aglietta, Carlo Barone, M. B. Sawyer,

Annals of Oncology

2014

216

Page 1